Group 1 - Company Tonghe Pharmaceutical recently announced the receipt of three invention patent certificates from the National Intellectual Property Administration of China [1] - The patents include methods for the preparation of key intermediates for Resmetirom, as well as methods and applications for pyrazine compounds and their nitro derivatives, and the preparation method for Upatacitinib intermediates [1]

Core Insights - The State Intellectual Property Office of China has granted a patent to Shijiazhuang Yiling Pharmaceutical Co., Ltd. for a method of in vitro release of Aprepitant injection, with the announcement number CN117250269B and application date of August 2023 [1] Company Overview - Shijiazhuang Yiling Pharmaceutical Co., Ltd. was established in 2003 and is located in Shijiazhuang City, focusing primarily on research and experimental development [1] - The company has a registered capital of 39.75 million RMB [1] - According to data from Tianyancha, the company has invested in 6 enterprises, participated in 13 bidding projects, and holds 446 patent records, along with 34 administrative licenses [1]

Core Viewpoint - Boji Pharmaceutical announced that its wholly-owned subsidiary, Xinglin Traditional Chinese Medicine Technology (Guangzhou) Co., Ltd., has received a patent certificate from the National Intellectual Property Administration for an invention titled "A Liver-targeted Alkylating Agent and Its Application" [1] Group 1 - The patent awarded is significant for the company's research and development efforts in targeted therapies [1] - The invention focuses on a specific application in liver treatment, indicating potential advancements in medical technology [1]

Core Viewpoint - Zhejiang Tianyu Pharmaceutical Co., Ltd. has applied for a patent for a preparation method of Azilsartan Ester Potassium Salt, indicating innovation in pharmaceutical manufacturing [1] Company Overview - Zhejiang Tianyu Pharmaceutical Co., Ltd. was established in 2003 and is located in Taizhou, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 3,479.77159 million RMB [1] - The company has invested in 22 enterprises and participated in 20 bidding projects [1] - It holds 9 trademark information and 75 patent information, along with 23 administrative licenses [1] Patent Details - The patent application, published as CN120441565A, was filed on January 2025 [1] - The preparation method involves crystallization of Azilsartan Ester with Potassium Octanoate in an organic solvent at a temperature of 30-50°C, followed by aging treatment for at least 10 hours [1] - The method results in high yield, good purity, low impurity content, and significantly increased potassium ion content, demonstrating good stability [1] - The process conditions are milder, reducing energy consumption and eliminating the need for complex devices, enhancing operational practicality [1]